These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 22414602)
61. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Hsu FY; Johnston PB; Burke KA; Zhao Y Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741 [TBL] [Abstract][Full Text] [Related]
62. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Toyokawa G; Seto T Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376 [TBL] [Abstract][Full Text] [Related]
63. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells. Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739 [TBL] [Abstract][Full Text] [Related]
64. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Ito M; Zhao N; Zeng Z; Chang CC; Zu Y Cancer Gene Ther; 2010 Sep; 17(9):633-44. PubMed ID: 20448669 [TBL] [Abstract][Full Text] [Related]
65. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216 [TBL] [Abstract][Full Text] [Related]
66. Next-generation sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL. Steinhilber J; Bonin M; Walter M; Fend F; Bonzheim I; Quintanilla-Martinez L PLoS One; 2015; 10(2):e0117780. PubMed ID: 25688981 [TBL] [Abstract][Full Text] [Related]
67. Inhibitors of the anaplastic lymphoma kinase. Mologni L Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599 [TBL] [Abstract][Full Text] [Related]
68. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144 [TBL] [Abstract][Full Text] [Related]
69. Pathobiology of ALK+ anaplastic large-cell lymphoma. Amin HM; Lai R Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389 [TBL] [Abstract][Full Text] [Related]
71. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer. Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043 [TBL] [Abstract][Full Text] [Related]